Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.64 |
| ▸ | MAOA | P21397 | 6/20 | 0.64 |
| ▸ | HTR2A | P28223 | 3/20 | 0.52 |
| ▸ | HTR2C | P28335 | 3/20 | 0.52 |
| ▸ | HTR2B | P41595 | 3/20 | 0.52 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14881816 | 0.78 | MAOB (1.00) | MAOBMAOAHTR2AHTR2CHTR2B | |
| SCHEMBL16019175 | 0.78 | MAOB (1.00) | MAOBMAOAHTR2AHTR2CHTR2B | |
| SCHEMBL16010002 | 0.78 | MAOB (1.00) | MAOBMAOAHTR2AHTR2CHTR2B | |
| SCHEMBL15542348 | 0.78 | MAOB (1.00) | MAOBMAOAHTR2AHTR2CHTR2B | |
| SCHEMBL6425606 | 0.78 | MAOB (1.00) | MAOBMAOAHTR2AHTR2CHTR2B | |
| SCHEMBL12477787 | 0.78 | MAOB (0.67) | MAOBMAOAHTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL15541773 | 0.76 | MAOB (1.00) | MAOBMAOAHTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL6427587 | 0.76 | MAOB (1.00) | MAOBMAOAHTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL15542031 | 0.76 | MAOB (1.00) | MAOBMAOAHTR2AHTR2CHTR2B | |
| SCHEMBL8845508 | 0.75 | MAOB (0.45) | MAOBMAOAKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180079709-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079709-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | MAOB 147/4885MAOA 135/4885HTR2A 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.